V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression

Urology

Volumn 57, Issue 1, 2001, Pages 199-204

  Nam, R K ^a   Toi, A ^a   Vesprini, D ^b   Ho, M ^b   Chu, W ^b   Harvie, S ^b   Sweet, J ^a   Trachtenberg, J ^a   Jewett, M A S ^a   Narod, S A ^b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

STEROID 5ALPHA REDUCTASE;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; RISK; TUMOR BIOPSY;

AGED; ALLELES; CHOLESTENONE 5 ALPHA-REDUCTASE; DISEASE PROGRESSION; FOLLOW-UP STUDIES; GENETIC MARKERS; HUMANS; LEUCINE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; ODDS RATIO; OXIDOREDUCTASES; PHENOTYPE; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; VALINE;

EID: 0035156454     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(00)00928-6     Document Type: Article

References (28)

1. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer
2. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer; intermediate-term results
3. Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer
4. The impact of family history on early detection of prostate cancer
5. The effect of castration and estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate
6. Prospective study of sex hormone levels and risk of prostate cancer
7. Androgen metabolism and prostate cancer; establishing a model of genetic susceptibility
8. Effect of the dual 5alpha-reductase inhibitor Pnu 157706 on the growth of Dunning R3327 prostatic carcinoma in the rat
9. Effect of early treatment of prostate cancer with 5alpha-reductase inhibitor turosteride in Dunning R3327 prostatic carcinoma in rats
10. A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats
11. Natural mutagenesis study of the human steroid 5alpha-reductase 2 isozyme
12. The molecular basis of steroid 5alpha-reductase deficiency in a large Dominican kindred
13. Differential gene expression of steroid 5alpha-reductase-2 in core needle biopsies from malignant and benign prostatic tissue
14. Response of rat and human prostatic cancers to the novel 5-alpha reductase inhibitor, SK&F 105657
15. Antiandrogens and 5-alpha reductase inhibition of the proliferation rate in PC-3 and DU-145 human prostatic cancer cell line
16. Genetic linkage mapping of the human steroid 5 alpha-reductase type 2 gene (SRD5A2) close to D2S352 on chromosome region 2p23-p22
17. A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase
18. Serum human glandular kallikrein-2 (hK2) protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen
19. Significance of the CAG repeat polymorphism of the androgen receptor gene in prostate cancer progression
20. Natural history of progression after PSA elevation following radical prostatectomy
21. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging
22. The V89L polymorphism in the 5-alpha reductase type-2 gene and risk of prostate cancer
23. Association of missense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA
24. Information on death certificates; cause for concern?
25. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer
26. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values
27. The value of serum prostate specific antigen determinations before and after radical prostatectomy